Publication

Challenges for pulmonary delivery of high powder doses

Sibum, I., Hagedoorn, P., de Boer, A. H., Frijlink, H. W. & Grasmeijer, F., 5-Sep-2018, In : International Journal of Pharmaceutics. 548, 1, p. 325-336 12 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Sibum, I., Hagedoorn, P., de Boer, A. H., Frijlink, H. W., & Grasmeijer, F. (2018). Challenges for pulmonary delivery of high powder doses. International Journal of Pharmaceutics, 548(1), 325-336. https://doi.org/10.1016/j.ijpharm.2018.07.008

Author

Sibum, Imco ; Hagedoorn, Paul ; de Boer, Anne Haaije ; Frijlink, Henderik Willem ; Grasmeijer, Floris. / Challenges for pulmonary delivery of high powder doses. In: International Journal of Pharmaceutics. 2018 ; Vol. 548, No. 1. pp. 325-336.

Harvard

Sibum, I, Hagedoorn, P, de Boer, AH, Frijlink, HW & Grasmeijer, F 2018, 'Challenges for pulmonary delivery of high powder doses', International Journal of Pharmaceutics, vol. 548, no. 1, pp. 325-336. https://doi.org/10.1016/j.ijpharm.2018.07.008

Standard

Challenges for pulmonary delivery of high powder doses. / Sibum, Imco; Hagedoorn, Paul; de Boer, Anne Haaije; Frijlink, Henderik Willem; Grasmeijer, Floris.

In: International Journal of Pharmaceutics, Vol. 548, No. 1, 05.09.2018, p. 325-336.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Sibum I, Hagedoorn P, de Boer AH, Frijlink HW, Grasmeijer F. Challenges for pulmonary delivery of high powder doses. International Journal of Pharmaceutics. 2018 Sep 5;548(1):325-336. https://doi.org/10.1016/j.ijpharm.2018.07.008


BibTeX

@article{8f708a85275b4320aea3d6cdd83f993d,
title = "Challenges for pulmonary delivery of high powder doses",
abstract = "In recent years there is an increasing interest in the pulmonary delivery of large cohesive powder doses, i.e. drugs with a low potency such as antibiotics or drugs with a high potency that need a substantial fraction of excipient(s) such as vaccines stabilized in sugar glasses. The pulmonary delivery of high powder doses comes with unique challenges. For low potency drugs, the use of excipients should be minimized to limit the powder mass to be inhaled as much as possible. To achieve this objective the inhaler design should be adapted to the properties of the API in order to achieve a compatible combination of the drug formulation and inhaler device. The inhaler should have an appropriate powder dosing principle for which prefilled compartments seem most appropriate. The drug formulation should not only allow for accurate filling of these compartments but also enable efficient compartment emptying during inhalation. The dispersion principle must have the capacity to disperse considerable amounts of powder in a short time frame that allows the powder to reach the deep lung. Last, but not least, the inhaler should be simple and intuitive in use, be cost-effective and exhibit accurate and consistent, preferably patient independent, pulmonary delivery performance.",
keywords = "High dose pulmonary delivery, Dry powder inhaler, Inhaler design, Drug formulation, Inhalation, SUPERCRITICAL CARBON-DIOXIDE, AIR CLASSIFIER TECHNOLOGY, DRUG-DELIVERY, IN-VITRO, ARTERIAL-HYPERTENSION, ALVEOLAR MACROPHAGES, PARKINSONS-DISEASE, SURFACE-PROPERTIES, ADHESIVE MIXTURES, BULK BEHAVIOR",
author = "Imco Sibum and Paul Hagedoorn and {de Boer}, {Anne Haaije} and Frijlink, {Henderik Willem} and Floris Grasmeijer",
year = "2018",
month = "9",
day = "5",
doi = "10.1016/j.ijpharm.2018.07.008",
language = "English",
volume = "548",
pages = "325--336",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier Bedrijfsinformatie b.v.",
number = "1",

}

RIS

TY - JOUR

T1 - Challenges for pulmonary delivery of high powder doses

AU - Sibum, Imco

AU - Hagedoorn, Paul

AU - de Boer, Anne Haaije

AU - Frijlink, Henderik Willem

AU - Grasmeijer, Floris

PY - 2018/9/5

Y1 - 2018/9/5

N2 - In recent years there is an increasing interest in the pulmonary delivery of large cohesive powder doses, i.e. drugs with a low potency such as antibiotics or drugs with a high potency that need a substantial fraction of excipient(s) such as vaccines stabilized in sugar glasses. The pulmonary delivery of high powder doses comes with unique challenges. For low potency drugs, the use of excipients should be minimized to limit the powder mass to be inhaled as much as possible. To achieve this objective the inhaler design should be adapted to the properties of the API in order to achieve a compatible combination of the drug formulation and inhaler device. The inhaler should have an appropriate powder dosing principle for which prefilled compartments seem most appropriate. The drug formulation should not only allow for accurate filling of these compartments but also enable efficient compartment emptying during inhalation. The dispersion principle must have the capacity to disperse considerable amounts of powder in a short time frame that allows the powder to reach the deep lung. Last, but not least, the inhaler should be simple and intuitive in use, be cost-effective and exhibit accurate and consistent, preferably patient independent, pulmonary delivery performance.

AB - In recent years there is an increasing interest in the pulmonary delivery of large cohesive powder doses, i.e. drugs with a low potency such as antibiotics or drugs with a high potency that need a substantial fraction of excipient(s) such as vaccines stabilized in sugar glasses. The pulmonary delivery of high powder doses comes with unique challenges. For low potency drugs, the use of excipients should be minimized to limit the powder mass to be inhaled as much as possible. To achieve this objective the inhaler design should be adapted to the properties of the API in order to achieve a compatible combination of the drug formulation and inhaler device. The inhaler should have an appropriate powder dosing principle for which prefilled compartments seem most appropriate. The drug formulation should not only allow for accurate filling of these compartments but also enable efficient compartment emptying during inhalation. The dispersion principle must have the capacity to disperse considerable amounts of powder in a short time frame that allows the powder to reach the deep lung. Last, but not least, the inhaler should be simple and intuitive in use, be cost-effective and exhibit accurate and consistent, preferably patient independent, pulmonary delivery performance.

KW - High dose pulmonary delivery

KW - Dry powder inhaler

KW - Inhaler design

KW - Drug formulation

KW - Inhalation

KW - SUPERCRITICAL CARBON-DIOXIDE

KW - AIR CLASSIFIER TECHNOLOGY

KW - DRUG-DELIVERY

KW - IN-VITRO

KW - ARTERIAL-HYPERTENSION

KW - ALVEOLAR MACROPHAGES

KW - PARKINSONS-DISEASE

KW - SURFACE-PROPERTIES

KW - ADHESIVE MIXTURES

KW - BULK BEHAVIOR

U2 - 10.1016/j.ijpharm.2018.07.008

DO - 10.1016/j.ijpharm.2018.07.008

M3 - Article

VL - 548

SP - 325

EP - 336

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1

ER -

ID: 64083695